Denali Therapeutics Inc. news DNLI
Plain-English coverage of this company’s material 8-K filings — generated from the primary source the moment they file.
← back to Denali Therapeutics Inc.-
High Positive
Denali Therapeutics (DNLI) Sells Priority Review Voucher for $195M
Denali Therapeutics will receive $195 million in gross proceeds from the sale of a rare pediatric disease priority review voucher awarded after the FDA approved...